|Mr. Dror Ben-Asher||Co-Founder, Chairman & CEO||333.32k||N/A||1966|
|Mr. Micha Ben-Chorin||Chief Financial Officer||223.8k||N/A||1969|
|Mr. Gilead Raday||Chief Operating Officer||302.2k||N/A||1975|
|Dr. Reza Fathi||Sr. VP of R&D||267.01k||N/A||1955|
|Mr. Guy Goldberg||Chief Bus. Officer||221.4k||N/A||1976|
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs. Its principal clinical-stage development programs comprise TALICIA (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria infections; BEKINDA (RHB-102) for acute gastroenteritis and gastritis and diarrhea-predominant irritable bowel syndrome; YELIVA (ABC294640) for cholangiocarcinoma, as well as targeting other oncology, inflammatory, and gastrointestinal indications; RHB-106, an encapsulated bowel preparation; and RHB-107 for cancer and inflammatory gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
RedHill Biopharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.